The Comprehensive Hereditary Cancer Panel is an advanced genetic test designed to identify inherited mutations associated with increased cancer risk. It analyzes multiple cancer-related genes linked to hereditary conditions affecting organs such as the breast, ovary, colon, prostate, and pancreas. The test helps assess an individual’s genetic predisposition to cancer, supports early detection and preventive care strategies, and assists healthcare providers in making personalized screening, surveillance, and treatment recommendations for patients and their families.
Individuals with strong family cancer history, early-onset cancers, multiple cancers, or relatives carrying hereditary cancer mutations may benefit from testing.
The panel commonly assesses hereditary risks for breast, ovarian, colorectal, prostate, pancreatic, gastric, uterine, and other inherited cancers.
The panel may include BRCA1, BRCA2, TP53, PALB2, MLH1, MSH2, APC, CHEK2, and several other cancer-associated genes.
A positive result identifies an inherited mutation associated with increased cancer risk and may require enhanced screening and preventive care.
A negative result means no significant inherited mutation was detected, though personal and family history may still influence cancer risk.
Yes, genetic counseling helps individuals understand test results, cancer risks, family implications, and appropriate medical management recommendations.
No, while comprehensive, the panel may not identify every hereditary cancer mutation or rare genetic alteration associated with cancer risk.
...
Didn't recieved OTP Yet? Resend OTP